Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Amgen Inc.    AMGN

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2020 11/20/2020 11/23/2020 11/24/2020 11/25/2020 Date
224.67(c) 223.17(c) 222.22(c) 220.46(c) 219.53 Last
2 595 657 2 956 252 2 033 413 3 199 050 1 427 716 Volume
-1.36% -0.67% -0.43% -0.79% -0.42% Change
More quotes
Financials (USD)
Sales 2020 25 380 M - -
Net income 2020 7 038 M - -
Net Debt 2020 18 313 M - -
P/E ratio 2020 18,6x
Yield 2020 2,90%
Sales 2021 26 410 M - -
Net income 2021 8 096 M - -
Net Debt 2021 14 401 M - -
P/E ratio 2021 15,8x
Yield 2021 3,07%
Capitalization 128 B 128 B -
EV / Sales 2020 5,78x
EV / Sales 2021 5,41x
Nbr of Employees 23 400
Free-Float 99,8%
More Financials
Company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN... 
Sector
Pharmaceuticals
Calendar
02/04Earnings Release
More about the company
Notations Surperformance© of Amgen Inc.
Trading Rating : Investor Rating :
More Ratings
All news about AMGEN INC.
02:55pAMGEN : On Pace for Eight-Day Losing Streak, Longest Since October 2017 -- Data ..
DJ
11/24AMGEN : to Transition Development and Commercial Rights for Omecamtiv Mecarbil a..
AQ
11/23AMGEN : Ending Heart-Failure Collaboration With Cytokinetics
DJ
11/20ENTERA BIO LTD : Announces Third Quarter 2020 Financial Results and Provides Cli..
AQ
11/20AMGEN : BeiGene Announces the Approval of XGEVA in China for the Prevention of S..
AQ
11/20AMGEN : Federal Court Of Appeal Upholds First Trial Judgment Under New PM(NOC) R..
AQ
11/20Pfizer suffers setback in ENBREL battle of patent infringement claim
AQ
11/13AMGEN : To Present At The Jefferies Virtual London Healthcare Conference
PR
11/13AMGEN : Cytokinetics heart failure drug succeeds but slightly higher death rate ..
RE
11/13AMGEN INC. : Ex-dividend day for
FA
11/11ASTRAZENECA : Tezepelumab NAVIGATOR Phase III trial met primary endpoint of a st..
AQ
11/10AMGEN : To Present At The Cowen 4th Annual IO Summit
PR
11/10ENTERA BIO LTD : Announces Completion of Enrollment in Phase 2 Clinical Trial of..
AQ
11/10ASTRAZENECA : Amgen Phase 3 Asthma Treatment Trial Meets Primary Endpoint -- Upd..
DJ
11/10AMGEN : Tezepelumab NAVIGATOR Phase III trial met primary endpoint of a statisti..
AQ
More news
News in other languages on AMGEN INC.
11/10Les valeurs à suivre aujourd'hui à Wall Street Mardi 10 novembre 2020
11/10AMGEN : résultats encourageants contre l'asthme
11/10WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
11/10WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street (actualisé)
11/02NOVARTIS : étude de suivi concluante pour l'anti-migraine Aimovig
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 251,24 $
Last Close Price 220,46 $
Spread / Highest target 37,9%
Spread / Average Target 14,0%
Spread / Lowest Target -16,1%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman, President & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
Peter H. Griffith Chief Financial Officer
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN INC.-8.55%128 345
JOHNSON & JOHNSON-1.37%378 744
ROCHE HOLDING AG-4.28%281 946
PFIZER INC.-6.59%203 437
MERCK & CO., INC.-11.89%202 757
NOVARTIS AG-12.66%200 273